Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17987317 | 0.86 | ALDH1A1 (0.59) | ALDH1A1MEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL17963607 | 0.81 | ALDH1A1 (0.60) | ALDH1A1MEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL17987537 | 0.79 | ALDH1A1 (0.59) | ALDH1A1MEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL17987541 | 0.76 | ALDH1A1 (0.62) | ALDH1A1MEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL20629820 | 0.76 | ALDH1A1 (0.65) | ALDH1A1MEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL17987118 | 0.75 | ALDH1A1 (0.64) | ALDH1A1MEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL17987481 | 0.75 | ALDH1A1 (0.64) | ALDH1A1MEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL17987394 | 0.75 | ALDH1A1 (0.64) | ALDH1A1MEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL17987535 | 0.75 | ALDH1A1 (0.64) | ALDH1A1MEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL20630352 | 0.74 | ALDH1A1 (0.63) | ALDH1A1MEN1KMT2ASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3250569-B1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-01-09 | — | — | EP | disclosed |
| EP-3250569-B1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-01-09 | — | — | EP | disclosed |
| US-10131642-B1 | Aldosterone synthase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-11-20 | — | — | US | disclosed |
| US-20180312475-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-11-01 | — | — | US | disclosed |
| WO-2016123275-A1 | ALDOSTERONE SYNTHASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312475-A1 | ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | ALDH1A1 250/4885MEN1 610/4885KMT2A 3968/4885 |
| US-10131642-B1 | Aldosterone synthase inhibitors | CYP21A2, CYP11B1, CYP17A1 | ALDH1A1 250/4885MEN1 610/4885KMT2A 3968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.